Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497441 | 0.88 | ESR2 (0.50) | CNR2ESR2KDM1AKCNH2MAOB | |
| SCHEMBL3497539 | 0.88 | ESR2 (0.50) | CNR2ESR2KDM1AKCNH2MAOB | |
| SCHEMBL5228850 | 0.88 | ESR2 (0.50) | CNR2ESR2KDM1AKCNH2MAOB | |
| SCHEMBL3496853 | 0.88 | ESR2 (0.50) | CNR2ESR2KDM1AKCNH2MAOB | |
| SCHEMBL1003122 | 0.81 | KDM1A (0.46) | ESR2KDM1AKCNH2MAOBRCOR1 | |
| SCHEMBL1003121 | 0.81 | KDM1A (0.46) | ESR2KDM1AKCNH2MAOBRCOR1 | |
| SCHEMBL2015709 | 0.81 | KDM1A (0.46) | ESR2KDM1AKCNH2MAOBRCOR1 | |
| SCHEMBL233178 | 0.81 | ESR2 (0.47) | ESR2KDM1AKCNH2MAOBRCOR1 | |
| SCHEMBL11484279 | 0.81 | CNR2 (0.59) | CNR2ESR2 | |
| SCHEMBL6365286 | 0.81 | CNR2 (0.59) | CNR2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737824-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005103032-A2 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245529-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | CNR2 102/4885ESR2 388/4885KDM1A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.